Charles River Laboratories International, Inc. $CRL Shares Acquired by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,742 shares of the medical research company’s stock after buying an additional 76 shares during the period. Exchange Traded Concepts LLC’s holdings in Charles River Laboratories International were worth $871,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in CRL. Goldman Sachs Group Inc. increased its holdings in shares of Charles River Laboratories International by 407.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company’s stock worth $150,142,000 after buying an additional 800,762 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company’s stock worth $85,811,000 after purchasing an additional 538,792 shares during the period. Royal Bank of Canada boosted its position in shares of Charles River Laboratories International by 304.7% during the 1st quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company’s stock worth $94,484,000 after purchasing an additional 472,606 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Charles River Laboratories International by 144.3% during the 1st quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company’s stock worth $82,007,000 after purchasing an additional 321,789 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of Charles River Laboratories International by 16,153.2% during the 1st quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company’s stock worth $40,219,000 after purchasing an additional 265,558 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. This trade represents a 3.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on CRL. Barclays increased their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 7th. Wall Street Zen cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Finally, Citigroup upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and increased their target price for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and an average price target of $177.07.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $150.18 on Wednesday. The firm has a market cap of $7.39 billion, a PE ratio of -112.91, a price-to-earnings-growth ratio of 4.11 and a beta of 1.47. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $230.02. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average is $160.10 and its two-hundred day moving average is $148.03.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. During the same period last year, the business earned $2.80 EPS. The company’s revenue was up .6% on a year-over-year basis. On average, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).